Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Benzinga · 2d ago
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.